摘要
目的本研究旨在探索Aurora—A在非小细胞肺癌（Non—smallcelllungcancer，NSCLC）的表达情况，以及其与化疗药耐药性和预后的关系。方法选取哈尔滨医科大学附属肿瘤医院，2010年5月—2013年10月收治的NSCLC患者纳入本次研究，共62例。所有患者均接受手术治疗，手术后接受顺铂为基础的化疗。制作组织芯片，Aurora—A在NSCLC组织的表达情况用免疫组化的方法进行检测，Au—rora—A与临床指标的关系进行相关分析，采J}}jKaplan—Meier单因素生存分析的方法进行总生存率的分析，应用Log—rank检验Aurora—A高表达组与低表达组之间的差异性。结果免疫组化检测结果显示，在62例患者中，26例患者为Aurora—A高表达。高表达组和低表达组两组患者年龄、性别构成比、TNM分期等差异均无统计学意义。高表达组中位生存时间为50．1个月，而低表达组中位生存时间为55．8个月，两组差异有统计学意义（P=0．047）。结论对于接受顺铂为基础的化疗的NSCLC患者，Aurora—A的高表达与不良预后相关。Aurora—A有望成为治疗NSCLC耐药性的新靶点。
Objective To identify the expression of Aurora - A and its correlation with cisplatin resist- ance and prognosis in non - small cell lung cancer（NSCLC）. Methods A total of 62 NSCLC patients treated by surgery and adjuvant cisplatin - based chemotherapy were included in our study. The expression of Aurora - A was determined by immunohistochemical （IHC） analysis. Correlation between Aurora - A expression and clinic pathological variables was estimated. The prognostic significances were assessed by Kaplan - Meier method, and the differences in survival probabilities were evaluated by the Log - rank test. Results IHC showed that 26 out of the 62 NSCLC patients were with high Aurora - A. There was no significant association between Aurora - A ex- pression and clinic pathological variables. The overall survival of patients with high Aurora -A expression（ median survival time ：50.1 months）was significantly poorer than those with low Aurora -A expression （median survival time：55.8 months）. Conclusion The present study suggests that high Aurora - A expression is correlated with cisplatin- based chemotherapeutic resistance and predicts poor patient survival in NSCLC. However, further in vitro study is needed.
出处
《实用肿瘤学杂志》
CAS
2016年第2期97-102,共6页
Practical Oncology Journal
基金
黑龙江省自然科学基金项目（D201238）
